MedTrace Logo

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

NCT03455764 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-07-31

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation.

The interventions involved in this study are:

* MCS110
* Dabrafenib
* Trametinib

Conditions

Interventions

DRUG

MCS110

MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

DRUG

Dabrafenib

Dabrafenib attack different proteins that promote the growth of cancerous cells

DRUG

Trametinib

Trametinib attack different proteins that promote the growth of cancerous cells

Sponsors & Collaborators

Principal Investigators

  • Elizabeth I Buchbinder, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-10
Primary Completion
2023-09-05
Completion
2023-09-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03455764 on ClinicalTrials.gov